(3-{6-[8-(4-Methyl-piperazin-1-yl)-imidazo[1,2-a]pyrazin-3-yl]-pyridin-2-ylamino}-3-phenyl-propyl)-carbamic acid tert-butyl ester → N1-{6-[8-(4-methyl-piperazin-1-yl)-imidazo[1,2-a]pyrazin-3-yl]-pyridin-2-yl}-1-phenyl-propane-1,3-diamine
反応式
C(OC(=O)[NH:7][CH2:8][CH2:9][CH:10]([NH:17][C:18]1[CH:23]=[CH:22][CH:21]=[C:20]([C:24]2[N:28]3[CH:29]=[CH:30][N:31]=[C:32]([N:33]4[CH2:38][CH2:37][N:36]([CH3:39])[CH2:35][CH2:34]4)[C:27]3=[N:26][CH:25]=2)[N:19]=1)[C:11]1[CH:16]=[CH:15][CH:14]=[CH:13][CH:12]=1)(C)(C)C>C(O)C.Cl>[CH3:39][N:36]1[CH2:35][CH2:34][N:33]([C:32]2[C:27]3[N:28]([C:24]([C:20]4[N:19]=[C:18]([NH:17][CH:10]([C:11]5[CH:16]=[CH:15][CH:14]=[CH:13][CH:12]=5)[CH2:9][CH2:8][NH2:7])[CH:23]=[CH:22][CH:21]=4)=[CH:25][N:26]=3)[CH:29]=[CH:30][N:31]=2)[CH2:38][CH2:37]1参加物
反応物 1
生成物 1
試薬・触媒・溶媒 2
実験手順
The solution of (3-{6-[8-(4-methyl-piperazin-1-yl)-imidazo[1,2-a]pyrazin-3-yl]-pyridin-2-ylamino}-3-phenyl-propyl)-carbamic acid tert-butyl ester (44 mg, 0.08 mmol) in ethanol (4 mL) and concentrated HCl (4 mL) was stirred at room temperature for 15 hours. The reaction mixture was then concentrated under reduced pressure. The residue was suspended in CH2Cl2 and concentrated under reduced pressure to give N1-{6-[8-(4-methyl-piperazin-1-yl)-imidazo[1,2-a]pyrazin-3-yl]-pyridin-2-yl}-1-phenyl-propane-1,3-diamine; hydrochloride. (Yield 25 mg). 1H NMR (300 MHz, CD3OD): δ 8.39 (s, 1H), 8.15 (s, 1H), 7.61 (t, 1H, J=5.7 Hz), 7.40-7.48 (m, 7H), 6.78 (brs, 1H), 5.39 (brs, 1H), 5.01 (brs, 1H), 3.81-3.66 (m, 4H), 3.37 (brs, 2H), 3.12-2.91 (m, 7H), 2.16-2.14 (m, 2H). LC-MS: [M+H]+ 443.
後処理
- concentrationThe reaction mixture was then concentrated under reduced pressure
- concentrationconcentrated under reduced pressure
出典と根拠
- ORDレコード
- ord-70ab128cdfa34787b015181af1fae25f
- 出典データセット
- uspto-grants-2014_03
- 特許番号
- US08673905B2
反応ノート
読み込み中…